chartexchange

CRVS
Corvus Pharmaceuticals, Inc.
stockNASDAQ

Market OpenNov 19, 2026 2:58:52 PM EST
10.09USD-0.981%(-0.10)427,212
Pre-marketNov 19, 2026 8:38:30 AM EST
10.15USD-0.393%(-0.04)
10.04Bid10.09Ask0.05Spread
Loading…
Loading…
851.12M
Healthcare
Biotechnology
CEO
Richard Miller
HQ
Burlingame, CA, USA
Previous Close
$10.19
Beta
-0.06
52-Week High
$26.95 2026-01-23
52-Week Low
$6.39 2026-01-12
SMA 50
$10.97
SMA 200
$13.83
Avg. Vol 10D
976,130
Avg. Vol 30D
1.03M
Avg. Vol 90D
978,397
Relative Vol
0.41
64.97M
17,759,451
0.2800%
CRVS Profile

corvus pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class agents that target the immune system to treat patients with cancer. with accomplished and talented scientists, and top-tier investors, we are well positioned in an exciting new era of immuno-oncology.

CRVS Performance
PeriodPriceDateChangeBeta
1W10.622026-11-12-4.99%0.637
1M9.652026-10-19+4.56%1.962
3M15.402026-08-19-34.48%1.862
6M11.502026-05-19-12.26%1.568
1Y8.902025-11-19+13.37%-0.064
2Y8.402024-11-19+20.12%—
5Y3.502021-11-19+188.29%1.069
CRVS Stock Summary

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) stock price today is $10.09, and today's volume is 424,253. CRVS is down 0.981% today. The 30 day average volume is 1.03M. CRVS market cap is $851.12M with 84.35M shares outstanding.